Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Quest receives U.S. patent allowance for cancer combination therapy

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease".

22 Jul 2011

Leading cancer specialists and researchers establish Australia’s first comprehensive ‘Cancer Survivors Centre’

Australia’s first comprehensive treatment and research centre for the growing number of cancer survivors will be announced at the annual Ride for Life luncheon at NSW Parliament House today.

22 Jul 2011

Taller women more prone to cancer: Study

New research has shown that taller women could be more prone to suffering from cancer. The British study published online in the medical journal The Lancet on Thursday said cancer risk rose about 16% for every 4-inch rise in height. Increasing height heightened the chances of cancers of breast, ovary, womb, bowel, leukemia and malignant melanoma (skin cancer) the study found.

21 Jul 2011

Public disclosure of Bachmann's migraine condition raises much-needed awareness

University of Vermont Professor of Neurology and migraine expert Robert Shapiro, M.D., Ph.D., says U.S. Representative and presidential candidate Michele Bachmann's public disclosure of her migraine condition has brought much-needed awareness to this disabling, often-stigmatized disorder, which afflicts millions of Americans.

21 Jul 2011

Normal stem cell encourages growth of cancer stem cells and fuels ovarian cancer

Researchers at the University of Michigan Comprehensive Cancer Center have found that a type of normal stem cell fuels ovarian cancer by encouraging cancer stem cells to grow.

20 Jul 2011

Aeterna's AEZS-108 final Phase 2 results in endometrial cancer to be presented at ESGO 2011

Aeterna Zentaris Inc. today announced that final Phase 2 results in endometrial cancer on its anticancer compound, AEZS-108, will be presented during a poster session at the upcoming 17th International Meeting of the European Society of Gynaecological Oncology, to be held September 11-14, 2011, at the Milan Convention Center in Milan, Italy.

19 Jul 2011

CVS Caremark adds Access' MuGard to pharmacy benefit network

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.

15 Jul 2011

Nature journal publishes landmark genetic study of ovarian cancer

A University of Houston researcher is an author on a landmark multi-institutional genetic study of the most aggressive and common form of ovarian cancer that is published in the current issue of the scientific journal Nature.

11 Jul 2011

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.

8 Jul 2011

Researchers use AFM to characterize ovarian cell structure for cancer diagnosis

Using ovarian surface epithelial cells from mice, researchers from Virginia Tech have released findings from a study that they believe will help in cancer risk assessment, cancer diagnosis, and treatment efficiency in a technical journal: Nanomedicine.

7 Jul 2011

Gene therapy may help prevent progression of type 1 diabetes

Increasing a specific protein in areas of the pancreas that produce insulin blocks the immune attack that causes type 1 diabetes, researchers reported in the August issue of the Journal of Clinical Investigation, published early online.

7 Jul 2011

Ovarian cells are stiffer and more viscous when benign

6 Jul 2011

Ovarian cancer molecular updates

In a new study a genetic mutation was found in the most common form of ovarian cancer. This according to the US scientists could pave the way for a more effective treatment of the disease. The detailed genetic map already helped scientists identify existing drugs with the potential for treating the mutations found in ovarian cancer tumors and also identified mutations that could respond to new drugs.

1 Jul 2011

TCGA examines ovarian serous adenocarcinoma tumors from 500 patients

An analysis of genomic changes in ovarian cancer has provided the most comprehensive and integrated view of cancer genes for any cancer type to date. Ovarian serous adenocarcinoma tumors from 500 patients were examined by The Cancer Genome Atlas (TCGA) Research Network and analyses are reported in the June 30, 2011, issue of Nature.

30 Jun 2011

Researchers develop way to uncover evolution of human cancer cells

A team of researchers led by scientists at the University of California, San Francisco has developed a way to uncover the evolution of human cancer cells, determining the order in which mutations emerge in them as they wend their way from a normal, healthy state into invasive, malignant masses.

30 Jun 2011

RHEI receives Chinese SFDA acceptance letter for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.

17 Jun 2011